Barclays PLC Acquires 40,717 Shares of Shattuck Labs, Inc. (NASDAQ:STTK)

Barclays PLC grew its holdings in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 299.5% during the third quarter, Holdings Channel.com reports. The institutional investor owned 54,311 shares of the company’s stock after purchasing an additional 40,717 shares during the quarter. Barclays PLC’s holdings in Shattuck Labs were worth $189,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in shares of Shattuck Labs by 8.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company’s stock valued at $266,000 after buying an additional 5,397 shares during the period. American Century Companies Inc. boosted its holdings in Shattuck Labs by 25.4% in the second quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock worth $183,000 after acquiring an additional 9,608 shares in the last quarter. Atom Investors LP acquired a new stake in Shattuck Labs in the third quarter valued at approximately $35,000. Readystate Asset Management LP bought a new stake in shares of Shattuck Labs during the third quarter valued at approximately $39,000. Finally, MetLife Investment Management LLC raised its position in shares of Shattuck Labs by 129.1% during the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the period. Institutional investors and hedge funds own 58.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on STTK. Citigroup downgraded shares of Shattuck Labs from a “buy” rating to a “neutral” rating and reduced their price target for the company from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a research report on Wednesday, October 2nd. Finally, HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Shattuck Labs currently has an average rating of “Hold” and a consensus price target of $8.67.

Insiders Place Their Bets

In other Shattuck Labs news, Director Redmile Group, Llc bought 133,371 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the purchase, the director now directly owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This represents a 2.47 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.50% of the stock is currently owned by insiders.

Shattuck Labs Price Performance

NASDAQ STTK opened at $1.27 on Tuesday. The company has a fifty day moving average price of $1.18 and a 200-day moving average price of $2.50. Shattuck Labs, Inc. has a 1 year low of $0.94 and a 1 year high of $11.76. The firm has a market cap of $60.63 million, a price-to-earnings ratio of -0.83 and a beta of 1.71.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.